KCR

KCR is a contract research organisation (CRO) that provides clinical trial and consulting services to the pharmaceutical, biotechnology and medical device industries. The company was founded in Poland in 1997 by Marek Kiecana as Kiecana Clinical Research, and over nearly three decades it grew into a mid-size international CRO operating across Western and Central-Eastern Europe as well as the United States. Its service portfolio spans clinical trial management, monitoring, pharmacovigilance, clinical trial and drug registration, data management, biostatistics, and quality assurance and control. KCR specialises in Phase I–IV clinical trials of medicinal products and medical devices, and also offers services as a Functional Service Provider (FSP). The company holds Research and Development Centre status granted by the Polish government and the French Crédit d'impôt recherche, and maintains an EN ISO 9001:2008 certificate. Its ICH GCP investigator training was recognised by TransCelerate Biopharma in June 2014 as meeting the organisation's highest criteria. KCR has conducted roughly 400 clinical trials across a wide range of indications during its history. KCR's international expansion included opening KCR U.S. Inc. in the United States in 2010, adding offices in Germany and the United Kingdom in 2014, and establishing the subsidiary KCR Placement, which recruits specialist staff for the pharmaceutical sector. In 2015 the company moved its head office from Warsaw to Berlin. By the mid-2010s it operated in 19 countries and employed more than 300 people. In 2024, ICON plc acquired KCR, integrating the mid-size CRO into one of the world's largest clinical research organisations. ICON, founded in Dublin in 1990, employs almost 40,200 people across 99 locations in 55 countries and provides global expertise in clinical development and commercialisation. The acquisition of KCR expanded ICON's full-service and functional service provision capabilities, particularly in Europe.

KCR was founded in 1997 in Poland by Marek Kiecana under the name Kiecana Clinical Research. The company was established as a contract research organisation serving the pharmaceutical, biotechnology and medical industries, and over its first two decades it conducted approximately 400 clinical trials across a wide range of therapeutic indications. In 2007, Adam Kruszewski became president of the management board. The following year, 2008, KCR acquired DUX Consulting and opened an office in Russia. In 2010, the company expanded into the United States by establishing KCR U.S. Inc. In 2013, Mike Jagielski became president of the management board, and KCR joined the Association of Clinical Trials Organizations in Russia. In 2014, KCR opened new offices in Germany and the United Kingdom, and established a subsidiary, KCR Placement, focused on recruiting specialist personnel for the pharmaceutical sector. That same year, KCR's ICH GCP investigator training was recognised by TransCelerate Biopharma as meeting the organisation's highest criteria. In 2015, the company relocated its head office from Warsaw to Berlin. By that time, KCR operated in 19 countries across Western and Central-Eastern Europe and the United States, and employed more than 300 people. KCR specialised in Phase I–IV clinical trials of medicinal products and medical devices, and offered services as a Functional Service Provider (FSP). It held Research and Development Centre status granted by the Polish government and the French Crédit d'impôt recherche, and maintained an EN ISO 9001:2008 certificate. In 2024, ICON plc acquired KCR, integrating the mid-size CRO into its global clinical development and commercialisation platform. ICON, founded in Dublin in 1990, employs almost 40,200 people in 99 locations across 55 countries. The acquisition of KCR expanded ICON's full-service and functional service provision capabilities, particularly in Europe.

• 2024

  ICON plc acquires KCR

• 2015

  KCR moves its head office from Warsaw to Berlin

• 2014

  KCR opens offices in Germany and the United Kingdom; establishes subsidiary KCR Placement; ICH GCP training recognised by TransCelerate Biopharma

• 2013

  Mike Jagielski becomes president of the management board; KCR joins the Association of Clinical Trials Organizations in Russia

• 2010

  KCR opens KCR U.S. Inc. in the United States

• 2008

  KCR acquires DUX Consulting and opens an office in Russia

• 2007

  Adam Kruszewski becomes president of the management board

• 1997

  KCR founded in Poland by Marek Kiecana as Kiecana Clinical Research

Mid-size CRO offering full-service and functional clinical trial services across Europe and the United States, now part of ICON plc.

• Clinical trial management

• Clinical monitoring

• Pharmacovigilance

• Clinical trial and drug registration

• Data management

• Biostatistics

• Quality assurance and control

• Functional Service Provider (FSP) services

• Phase I–IV clinical trials

• ICH GCP investigator training

1. 1Biotech | Outsourcing Services | ICON plciconplc.com
2. 2Global CRO | Acquisitions & History | ICON plciconplc.com
3. 3ICON | Global CRO | Clinical development and commercialisationiconplc.com
4. 4ICON plc | Qualityiconplc.com
5. 5KCR S.A. - Wikidatawikidata.org
6. 6KCR - Wikipedia (Polish)pl.wikipedia.org